Four Health and AN Strategic Cooperation Signing
Recently, Suzhou Four Health Pharmaceuticals Co., Ltd. and Alpha Nuclide (Ningbo) Medical Technology Co., Ltd. have signed a strategic cooperation agreement.
Four Health and AN will focus on the research and development of precision-targeted alpha therapy nuclear medicine, primarily centered around 211At, and aim to globally promote and apply alpha nuclide therapy products based on 211At. This collaboration will lay a solid foundation for innovative nuclear medicine product development, clinical application, and commercial promotion. AN will ensure a long-term and stable supply of various medical isotopes required for Four Health’s research and development. Both parties are committed to implementing multi-level and multi-dimensional in-depth cooperation over the long term.
Therapeutic nuclear medicine has been experiencing a “Renaissance” globally in recent years.By precisely delivering to the lesion site through targeted carriers, therapeutic radionuclide drugs can selectively kill cancer cells with high accuracy, representing the forefront of nuclear medicine research and promising vast market potential in the future.
211At, characterized by its single alpha decay accompanied by X-rays, facilitates integrated diagnosis and treatment. It offers simple safety measures, no nuclear waste risk for end-users, and low safety management costs, making it one of the most promising alpha nuclides. The supply of 211At is plentiful, with the raw material being natural bismuth metal. Production only requires an accelerator, with each cycle taking just 4 hours, resulting in a fast turnover and independence from imports, thereby addressing the critical issue of isotope supply.
AN, as the sole Chinese representative of the World Astatine Community, is dedicated to becoming the first enterprise in China to specialize in the commercial supply of alpha nuclides. The core technical team consists of talents from international institutions and universities, such as Duke University, the University of Pennsylvania, the University of Missouri’s nuclear reactor, and Brookhaven National Laboratory. These experts have been deeply involved in the field of alpha nuclide cancer therapy for many years, particularly in the field of 211At, one of the most promising alpha nuclides, with leading global technological expertise.
AN has designed and manufactured the world’s first commercial 30 MeV alpha cyclotron, TR-Alpha, capable of uninterrupted 24-hour production, with a capacity of 400mCi per batch every 4 hours, and a daily production capacity exceeding 2000 mCi (the estimated dose for each patient is approximately 5-10 mCi). This provides a highly competitive cost for the use of alpha nuclides, significantly reducing the cost of terminal drug prices, and benefiting patients.